BridgeBio Oncology Therapeutics, Inc
Financing
SEC filings to 2026-10-05 · every row opens its filingShares on issue
80.1M
on 2026-06-30, from 79.2M on 2025-09-30 10-Q ↗
Counts before 2025-09-30 are left out: the count went from 28K on 2024-12-31 to 79.2M on 2025-09-30, a change no split on file explains.
a raise that quarter, at its price
Newest
$500.0M
S-3 of 2026-09-01. Sales under the at-the-market programme filed with it are not stated apart. S-3 ↗
$200.0M
Leerink Partners, agreement of 2026-09-01. No at-the-market sales statement read from a 10-Q or 10-K. S-3 ↗
Warrants
The 10-Q filed 2026-08-11 is not read yet.
Cash
4.7 quarters
$225.7M on 2026-06-30 ÷ $48.3M a quarter of operating cash used, the average of four quarters. 10-Q ↗
| Date | What | Shares | Price | Gross | Filing |
|---|---|---|---|---|---|
| 2025-07-10 | Public offering | not read | not read | not read | 424B4 ↗ |